Knight Therapeutics (GUD) Price & Analysis

Compare

100 Followers

GUD Stock Chart & Stats

Day’s Range― - ―

52-Week RangeC$5.09 - C$6.45

Previous CloseN/A

Volume40.10K

Average Volume (3M)44.34K

Market Cap

C$599.75M

Enterprise ValueC$541.52M

Total Cash (Recent Filing)C$180.86M

Total Debt (Recent Filing)C$53.92M

Price to Earnings (P/E)54.7

Beta0.28

Next Earnings

Aug 07, 2025

EPS Estimate

0.02

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.02

Shares Outstanding99,626,620

10 Day Avg. Volume48,614

30 Day Avg. Volume44,343

Financial Highlights & Ratios

PEG Ratio0.40

Price to Book (P/B)0.75

Price to Sales (P/S)0.00

P/FCF Ratio-39.52

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

C$8.04

Price Target Upside33.53% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

Knight Therapeutics News

PremiumThe Fly

Knight Therapeutics closes acquisition of Paladin

1d ago

PremiumThe Fly

Knight Therapeutics closes $50M revolving credit facility

1d ago

PremiumCompany Announcements

Knight Therapeutics Secures US$50 Million Credit Facility to Fuel Growth

1d ago

PremiumRatings

Knight Therapeutics Secures Strategic Licensing Agreement with Sumitomo Pharma America, Boosting Market Potential and Investment Appeal

11d ago

PremiumCompany Announcements

Knight Therapeutics’ Earnings Call: Growth Amid Challenges

1M ago

PremiumRatings

Knight Therapeutics: Strong Buy Rating Amid Promising Financial Outlook and Strategic Resilience

1M ago

PremiumCompany Announcements

Knight Therapeutics Sees Revenue Growth Amid Strategic Moves

1M ago

PremiumThe Fly

Knight Therapeutics sees FY25 revenue C$390M-C$405M

1M ago

See All TSE:GUD News

See All News >

Bulls Say, Bears Say

Bulls Say

AcquisitionThe acquisition of the Paladin business unit from Endo Inc. is expected to be immediately accretive, potentially enhancing Knight's financial performance.

Licensing AgreementKnight's exclusive Canadian licensing agreement with Sumitomo Pharma America for Myfembree, Orgovyx, and Vibegron could boost its market presence and revenue potential.

Revenue GrowthRevenues are projected to increase due to a new $22.4M contract with the Brazilian Ministry of Health, indicating strong business prospects.

Bears Say

Currency And Inflation ImpactFX and hyperinflation have skewed topline results, potentially affecting Knight's financial stability and predictability.

Sales PerformanceThe portfolio of assets generated only $11.2M of revenue in the last fiscal year, which might raise questions about asset performance.

Topline EstimatesKnight reported results that missed topline estimates, which could lead to concerns about meeting market expectations.

Financials

Income Statement >

Options Prices

Currently, No data available

---

Ownership Overview

30.35% Insiders

2.90%

Mutual Funds

0.09% Other Institutional Investors

66.05% Public Companies and

Individual Investors

Detailed Ownership Overview >

GUD FAQ

What was Knight Therapeutics’s price range in the past 12 months?

Knight Therapeutics lowest stock price was C$5.08 and its highest was C$6.45 in the past 12 months.

What is Knight Therapeutics’s market cap?

Knight Therapeutics’s market cap is C$599.75M.

When is Knight Therapeutics’s upcoming earnings report date?

Knight Therapeutics’s upcoming earnings report date is Aug 07, 2025 which is in 50 days.

How were Knight Therapeutics’s earnings last quarter?

Knight Therapeutics released its earnings results on May 08, 2025. The company reported C$0.02 earnings per share for the quarter, beating the consensus estimate of C$0.005 by C$0.015.

Is Knight Therapeutics overvalued?

According to Wall Street analysts Knight Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Knight Therapeutics pay dividends?

Knight Therapeutics does not currently pay dividends.

What is Knight Therapeutics’s EPS estimate?

Knight Therapeutics’s EPS estimate is 0.02.

How many shares outstanding does Knight Therapeutics have?

Knight Therapeutics has 99,626,620 shares outstanding.

What happened to Knight Therapeutics’s price movement after its last earnings report?

Knight Therapeutics reported an EPS of C$0.02 in its last earnings report, beating expectations of C$0.005. Following the earnings report the stock price went down -6.425%.

Which hedge fund is a major shareholder of Knight Therapeutics?

Currently, no hedge funds are holding shares in TSE:GUD

Company Description

Knight Therapeutics

Knight Therapeutics Inc. (GUD) is a specialty pharmaceutical company focused on acquiring or in-licensing pharmaceutical products for the Canadian and select international markets. The company primarily operates within the healthcare sector, specifically in pharmaceuticals, and offers a portfolio of branded prescription pharmaceuticals, over-the-counter products, and medical devices. Knight aims to provide innovative and niche products that address unmet medical needs, enhancing the quality of healthcare for patients.

GUD Earnings Call

Q1 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call presented a mixed picture with notable revenue growth and strategic acquisitions offset by a decline in adjusted EBITDA, financial asset losses, and increased operating expenses. While there are promising developments in the promoted portfolio and upcoming product launches, financial challenges need to be addressed.Read More>

GUD Stock 12 Month Forecast

Average Price Target

C$8.04

▲(33.53%Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"C$3","5":"C$5","7":"C$7","9":"C$9","11":"C$11"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":10.0757802332,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">C$10.08</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8.0387500368,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">C$8.04</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6.5485735844,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">C$6.55</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,5,7,9,11],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2024","6":"Apr<br/>2024","9":"Nov<br/>2024","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.75,6.08275232563077,6.415504651261538,6.748256976892308,7.081009302523077,7.413761628153846,7.746513953784616,8.079266279415386,8.412018605046153,8.744770930676923,9.077523256307693,9.41027558193846,9.743027907569232,{"y":10.0757802332,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.75,5.926057695138462,6.102115390276923,6.278173085415385,6.454230780553846,6.630288475692308,6.8063461708307695,6.98240386596923,7.158461561107693,7.334519256246153,7.510576951384616,7.686634646523077,7.862692341661538,{"y":8.0387500368,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.75,5.811428737261538,5.872857474523077,5.934286211784615,5.995714949046154,6.057143686307692,6.118572423569231,6.180001160830769,6.241429898092307,6.302858635353846,6.364287372615385,6.425716109876923,6.487144847138461,{"y":6.5485735844,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.94,"date":1688169600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.83,"date":1690848000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.61,"date":1698796800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.22,"date":1704067200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.37,"date":1706745600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.53,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.32,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.77,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.67,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.65,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.49,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.13,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.75,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >